Malignant pleural mesothelioma
Also known as: MPM, Pleural mesothelioma, Malignant mesothelioma of the pleura
Malignant pleural mesothelioma is an aggressive malignancy of the pleural lining, predominantly associated with asbestos exposure and exhibiting a protracted latency period. Specialist respiratory and oncology involvement is mandatory for definitive diagnosis, staging, and multimodal management. Current clinical literature outlines BAP1 prognostic factors and retrospective outcomes for systemic therapies rather than evaluating TCM efficacy; similarly, preclinical narciclasine studies and porcine models fail to establish clinical benefit. No cited evidence evaluates acupuncture or the specified formulas for mesothelioma. Within a coordinated oncology and palliative care framework, TCM pattern assessment may provide a traditional diagnostic lens for adjunctive symptom support. This support serves only as an adjunct to, not a replacement for, medical investigation, pleural interventions, or antineoplastic treatment, and must not delay urgent assessment for clinical deterioration.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Maintain a daily clinical log of dyspnoea, pain, cough, and body temperature to facilitate medical review, noting the impact on functional status.
- •Consume small, frequent, nutrient-dense meals if anorexia is present; seek formal dietetic consultation for weight loss rather than adopting restrictive, non-validated 'anticancer' dietary regimens.
- •Balance gentle physical activity with rest according to respiratory specialist recommendations; cease activity immediately if dizziness, dyspnoea, or chest pain occurs.
- •Avoid tobacco smoke and further asbestos exposure; engage licensed professionals for the remediation of suspected asbestos-containing materials rather than attempting self-removal.
Cautions & Contraindications
- •Do not substitute acupuncture, formulas or narciclasine products for oncology treatment. Narciclasine findings are from tumour spheroids and do not establish human efficacy, safe dosing or suitability for clinical use.[]
- •Before needling or herbal treatment during systemic therapy, obtain current oncology advice on blood counts, infection risk, bleeding risk and interactions. Defer needling with fever, active infection or clinically significant cytopenias pending clearance. These are general precautions, not thresholds tested in the supplied retrospective study.[]
- •Avoid needling over the chest, tumour, pleural catheters, surgical wounds, ports or irradiated or infected skin. Thoracic anatomy and treatment complications require specialist coordination; the cited review supports malignancy context, not acupuncture safety evidence.[]
- •Do not use hypoxia exposure, oxygen restriction or animal-model findings to guide patient treatment. The porcine and cell experiments do not demonstrate clinical benefit or establish a supportive-care protocol.[]
When to reassess or seek care again
If oncology agrees to a symptom-focused adjunctive trial, review after 1–2 weeks or 2–3 visits. Record 0–10 pain, breathlessness and fatigue scores, sleep disruption, intake, functional activity and adverse effects; monitor weight weekly where appropriate. Stop or revise care if there is no meaningful patient-reported improvement within 2–4 weeks. New or worsening respiratory symptoms, fever, bleeding, declining intake or function require prompt medical review rather than a pattern change alone. Cancer response remains assessed by the oncology team.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Clinical Medicine Insights. Oncology · 2026
- Journal of thoracic disease · 2025
- BMC cancer · 2025
- International journal of molecular sciences · 2025
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
